SAN DIEGO, June 16 /PRNewswire/ --

Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today that the Company's vice president of corporate development, Richard Lai Fatt, Ph.D., is scheduled to present a Company overview at the Business Forum during the Biotechnology Industry Organization 2008 International Convention being held in San Diego, California, July 17-20, 2008. The presentation will take place on Wednesday, June 18, 2008, at 3:45 p.m. PDT in Room 5B at the San Diego Convention Center.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Dr. Lai Fatt will discuss the Company's progress with its lead product candidate, HspE7, a novel compound intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. The presentation will not be webcast.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.

Web site: http://www.nventacorp.com

Donna Slade, Director, Investor Relations of Nventa Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com; or media, Tim Brons of Vida Communication, +1-415-675-7402, tbrons@vidacommunication.com; or Michael Moore of The Equicom Group, +1-416-815-0700, ext. 241, mmoore@equicomgroup.com, both for Nventa Biopharmaceuticals Corporation /Photo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO , AP Archive: http://photoarchive.ap.org , PRN Photo Desk, photodesk@prnewswire.com